double-blind trial mazindol Duchenne dystrophy evidence growth hormone progression weakness Duchenne dystrophy controlled trial mazindol putative growth hormone secretion inhibitor boys Duchenne dystrophy Muscle strength contractures functional ability pulmonary function baseline months treatment mazindol mg/d placebo study power slowing expected rate progression weakness strength point study Side effects attributable decreased appetite dry mouth behavioral change gastrointestinal symptoms mazindol dosage patients effect mazindol GH secretion postabsorptive IGF-I levels months mazindol placebo groups mazindol-treated patients weight height placebo-treated patients significant effect IGF-I levels Mazindol progression weakness Duchenne dystrophy 